Abstract
Type 2 diabetes (T2D) elevates Parkinson's disease (PD) risk, yet Hemoglobin A1c (HbA1c) implications on PD survival are unclear. This study assessed HbA1c's influence on PD survival. PD patients from the UK Biobank were divided into T2D-PD and nonT2D-PD groups. Adjusting for age, sex, townsend deprivation index, and body mass index, Cox regression analysis revealed that T2D-PD patients with HbA1c ≥ 43.1 mmol/mol had an increased mortality risk. No significant difference in mortality rates was observed between T2D-PD patients with HbA1c < 43.1 mmol/mol and nonT2D-PD patients. HbA1c may serve as a survival biomarker for T2D-PD patients.